July 18, 2018
Expanding Opportunities in Asia
SOMERVILLE, MA— June 9, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced that its Chief Executive Officer, Chris Adams, will present at the Chinese Biopharmaceutical Association (CBA) USA conference. The CBA conference will take place on June 9, 2018 in Gaithersburg, MD.
“The CBA conference offers Andarix the opportunity to present its findings and share its clinical message on a global stage in front of audience with extensive connections in the Chinese market”, say Chris Adams, CEO of Andarix.
About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer patients. Along with its companion diagnostic that helps identify patients most likely to respond – those with enough expression of the peptide’s target – Tozaride could provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are
highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors. To learn more about Andarix, please visit www.andarix.com.
About CBA
CBA’s primary mission is to bridge the biopharmaceutics gap between US and China. Headquartered in Maryland, CBA currently has more than 700 active members, over 3000 registered individual members, and more than 60 institutional members. Most CBA members belong to local biopharmaceutical companies, universities, research institutions, and government agencies. In addition to US members, CBA also has members residing in China, Europe, Canada, Australia, Singapore, and Japan.
Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com